As a specific cyclin-dependent kinase 4/6 inhibitor,palbociclibimproved the prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.Emerging data showed...As a specific cyclin-dependent kinase 4/6 inhibitor,palbociclibimproved the prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.Emerging data showed that palbociclib shed a new therapeutic regimen forbreast cancers and playsan essentialmilestone in the development of anti-tumor drugs,especially for advanced breast cancer.In this minireview,we aimed to summarize the mechanism,clinical application,and side effectsof palbociclib.展开更多
文摘As a specific cyclin-dependent kinase 4/6 inhibitor,palbociclibimproved the prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.Emerging data showed that palbociclib shed a new therapeutic regimen forbreast cancers and playsan essentialmilestone in the development of anti-tumor drugs,especially for advanced breast cancer.In this minireview,we aimed to summarize the mechanism,clinical application,and side effectsof palbociclib.
